Dublin, Jan. 11, 2017 -- Research and Markets has announced the addition of the "FDA's Medical Device Software Regulation Strategy: 2-Day In-Person Seminar by Ex-FDA Official" conference to their offering.
The growth of the medical software industry outpaces the design of FDA's regulatory process. In some instances clinicians have weighed the risk of software failure against the benefits of using a device at all. Device software is often used in conjunction with other software-based devices, but their interoperability was never anticipated.
- How can you anticipate and defend against the malicious remote hacking and shut down of an insulin infusion pump?
- Can one software program defeat the performance capability or back up safety features of another software program?
- When interoperability surface, which software manufacturer takes the lead to solve the problem and deal with proprietary software issues?
This seminar will focus on addressing these concerns and educating participants on FDA's recent medical device software regulation strategies.
This seminar will help those involved in overcoming these commercial and regulatory obstacles. It will highlight the need for firms to remain current with technological tools and strategy to remain competitive, and ideally, outside FDA's regulatory radar.
Agenda:
Day One (8:30 AM - 4:30 PM)
Registration Process: 8:30 AM - 9:00 AM
Session Start Time: 9:00 AM
FDA Authority and Regulatory Program
- Types of Software Devices
- Regulatory Strategy
- Risk Classification
- Function and outcome
Medical Device Data Systems (MDDS)
- Office of the National Coordinator (ONC) for Health Information Protection
- Software Regulatory Applications
- FDA Guidance
- Premarket submissions
- Paradigms: aeronautics
- Quality System Regulation (QSR)
- Design verification and validation
- Voluntary standards
- Corrective and prevent action plans
- Voluntary Standards
- Recalls:
- Service / maintenance / recall
- Implementation strategy
- Corrections and Removals Reporting
- Updates: FDA vs. Non-FDA
- Predictive Analytics
Interoperability
- Compatibility by Design
- Hardware
- Software
- Labeling
- Precautions
- Instructions for use
- Use of Voluntary Standards
- Proprietary Information
- Failure Management / Follow Up
- User's vs. Manufacturer's Legal Responsibility
- System configuration
- Customization
- Environment of use
- Professional
- Home use
Day Two (8:30 AM to 4:30 PM)
Cybersecurity
- Device Vulnerabilities: Malfunction and Failure
- Pre-Emption Design
- Latent Malware/Virus
- Post-Event Management
- Corrective action for software
- Disclosure to users
- National Institute of Science and Technology Report
Medical Mobile Applications (Mobile Apps)
- Mobile Apps Defined as a Device
- FDA Regulatory Strategy
- FDA Guidance
- National Institute of Science and Technology Report and Collaboration
- Updates (FDA vs. Non-FDA Updates)
- Criteria for corrective and preventive action deemed recalls
- Reports of corrections and removals
- Reports of adverse events
- Professional vs. Lay Use / Home Use
- Labeling: Instructions for Use and Precautions
- Environment of Use
- FDA Regulation of Accessories
- Federal Communications Commission (FCC) Regulation
For more information about this conference visit http://www.researchandmarkets.com/research/wbhxzz/fdas_medical
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Medical Devices


Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 



